Advanced Hepatocellular Carcinoma Clinical Trial
Official title:
Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy: a Randomized Controlled, Single-center Clinical Trial
This study plans to observe the changes of liver cancer and immune cell subsets by replicating the high abundance intestinal flora and liver cancer mouse model, reveal the relationship and mechanism of intestinal flora in the immunotherapy of liver cancer, and study the impact on prognosis by regulating the positive correlation of lactic acid bacteria and bifidobacteria of rumen coccus in patients with advanced liver cancer receiving immunotherapy
Select patients with advanced hepatocellular carcinoma who have been clinically consulted by MDT,those patients will be treated with carrilizumab and apatinib mesylate, and divide them into two groups randomly .Collect the stool specimens and clinical data from those who will be treated with oral bifidobacterium or without bifidobacterium during immunotherapy.; Use 16S sequencing to detect the changes in the composition ratio of intestinal flora and the level of galactose acid, judge the response to clinical treatment and establish the relationship curve with clinical treatment efficacy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
| Recruiting |
NCT05057845 -
Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02632006 -
Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02638857 -
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00752063 -
Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT00517920 -
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
| Recruiting |
NCT05797805 -
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05070156 -
B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma
|
Early Phase 1 | |
| Not yet recruiting |
NCT06092112 -
A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma
|
Early Phase 1 | |
| Recruiting |
NCT01214343 -
Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
|
Phase 3 | |
| Completed |
NCT00999882 -
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients
|
Phase 1 | |
| Withdrawn |
NCT00756782 -
A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT00534664 -
Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04503902 -
Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT04777708 -
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
|
Early Phase 1 | |
| Completed |
NCT04072679 -
Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
| Suspended |
NCT04066660 -
Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)
|
N/A | |
| Withdrawn |
NCT05592197 -
Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT
|
N/A | |
| Completed |
NCT02528643 -
A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 |